Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
NVO Stock News and Mentions of Novo Nordisk A/S Stocktwits
Updated: April 28, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Novo Nordisk Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Novo Nordisk A/S (NVO).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Novo Nordisk stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Novo Nordisk A/S (NVO)
April 28, 2024 (14:30) / "Motley Fool" (by George Budwell)
Is Viking Therapeutics Incredibly Undervalued?
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
In Article Trend: Neutral
April 28, 2024 (11:30) / "CNN" (by Nicole Goodkind)
What is divestment? And does it work? | Business
What is divestment? And does it work? CNN International ...
In Article Trend: Neutral
April 28, 2024 (11:30) / "CNN" (by Nicole Goodkind)
What is divestment? And does it work? | Business
What is divestment? And does it work? ...
In Article Trend: Neutral
April 27, 2024 (15:10) / "Motley Fool" (by David Jagielski)
Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
In Article Trend: Somewhat-Bullish
April 27, 2024 (13:15) / "Motley Fool" (by Adam Spatacco)
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
In Article Trend: Somewhat-Bullish
April 26, 2024 (22:17) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Apple, Amazon, Big Pharma And The Fed: Investing Action Plan
A Big Week For The Stock Market: Apple, Amazon, Big Pharma And The Fed Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (21:20) / "Investors Business Daily" (by ED CARSON)
Nvidia Leads 7 Stocks Flashing Buy Signals; As Market Roars Back
Dow Jones Futures: Nvidia Leads 7 New Buys As Market Roars. Fed, Apple, Super Micro Loom Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 26, 2024 (15:34) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
In Article Trend: Somewhat-Bullish
April 26, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years - Novo Nordisk ( NYSE:NVO )
Novo Nordisk NVO has outperformed the market over the past 10 years by 8.67% on an annualized basis producing an average annual return of 19.12%. Currently, Novo Nordisk has a market capitalization of $565.70 billion.
In Article Trend: Somewhat-Bullish
April 26, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Microsoft ( MSFT ) Q3 Earnings & Revenues Beat on Cloud Strength
Microsoft's (MSFT) third-quarter fiscal 2024 results reflect strength in the Azure business and Office 365, boosted by growing AI Copilot business.
In Article Trend: Somewhat-Bullish
April 26, 2024 (10:16) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
Bagsværd, Denmark, 26 April 2024 - In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.
In Article Trend: Somewhat-Bullish
April 26, 2024 (09:00) / "Financial Times" (by Oliver Barnes)
Its blockbuster cystic fibrosis treatment costs $300,000 a year. Now Vertex wants to solve the opioid crisis
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers ...
In Article Trend: Neutral
April 26, 2024 (01:45) / "Motley Fool" (by Motley Fool Transcribing)
Microsoft ( MSFT ) Q3 2024 Earnings Call Transcript
MSFT earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 25, 2024 (21:31) / "PR Newswire" (by LLP)
Global Urine Output Monitoring Systems Market is Projected to Grow at a CAGR of ~5% by 2030 | DelveInsight
The increasing occurrence of kidney disorders worldwide and the healthcare sector's increased focus on consistent monitoring and effective management of these conditions are expected to drive the demand for urine output monitoring systems between 2024 and 2030.
In Article Trend: Somewhat-Bullish
April 25, 2024 (14:30) / "Motley Fool" (by James Brumley)
3 Millionaire-Maker Biotech Stocks
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
In Article Trend: Somewhat-Bullish
April 25, 2024 (13:49) / "Zacks Commentary" (by Zacks Equity Research)
4 Blackrock Mutual Funds to Build a Solid Portfolio
Invest in Blackrock mutual funds like BMCAX, BIRAX, MDBAX and BREAX that have given impressive returns in the past and are expected to do the same in 2024 and beyond.
In Article Trend: Somewhat-Bullish
April 25, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
In Article Trend: Somewhat-Bullish
April 24, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
In Article Trend: Neutral
April 24, 2024 (21:03) / "CNN" (by Tami Luhby)
Sanders launches Senate investigation into 'outrageously high' pricing of Ozempic, Wegovy
Sanders launches Senate investigation into 'outrageously high' pricing of ...
In Article Trend: Neutral
April 24, 2024 (19:22) / "CNBC" (by Ryan Anastasio)
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.
In Article Trend: Neutral
April 24, 2024 (18:14) / "Benzinga" (by Vandana Singh)
What's Going On With Novo Nordisk Stock Today? - Novo Nordisk ( NYSE:NVO )
The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing Novo Nordisk A/S NVO 's pricing strategies, particularly those of its diabetes and obesity medications, Ozempic and Wegovy.
In Article Trend: Somewhat-Bullish
April 24, 2024 (14:09) / "Zacks Commentary" (by Kinjel Shah)
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
In Article Trend: Somewhat-Bullish
April 24, 2024 (13:25) / "Zacks Commentary" (by Kinjel Shah)
Should Eli Lilly ( LLY ) Be in Your Portfolio Ahead of Q1 Earnings?
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
In Article Trend: Somewhat-Bullish
April 24, 2024 (13:24) / "Investors Business Daily" (by Investor's Business Daily)
Weight Loss Leader Hits Buy Trigger In Market Rebound
Wednesday's IBD 50 Stocks To Watch pick, weight-loss drug leader Novo Nordisk ( NVO ) , hit an early buy trigger during the recent stock market rebound. That makes Novo Nordisk stock one of the best stocks to watch right now.
In Article Trend: Somewhat-Bullish
April 24, 2024 (12:48) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - Reduction of the share capital
Bagsværd, Denmark, 24 April 2024 - At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK ...
In Article Trend: Somewhat-Bullish
April 24, 2024 (10:40) / "Motley Fool" (by Adria Cimino)
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem.
In Article Trend: Neutral
April 24, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
In Article Trend: Somewhat-Bullish
April 23, 2024 (17:49) / "Benzinga" (by Zacks)
3 Healthcare Mutual Funds To Grab As the Sector Continues to Rebound - SPDR Select Sector Fund - Health Care ( ARCA:XLV )
Healthcare did not have a great 2023, even as markets turned around from the depths of the year prior. The sector, which roughly accounts for 13% of the S&P 500, lagged last year as investors flocked to massive tech and growth stocks that propelled the markets.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:36) / "CNBC" (by Rachel Curry)
Less burnout for doctors, better clinical trials, among the benefits of AI in health care
Artificial intelligence has traditionally been used to make healthcare safer and better. Now generative AI is making efficency a priority.
In Article Trend: Neutral
April 23, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Boasts Earnings & Price Momentum: Should You Buy?
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:15) / "Motley Fool" (by George Budwell)
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment?
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:15) / "Motley Fool" (by George Budwell)
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies.
In Article Trend: Somewhat-Bullish
April 23, 2024 (10:19) / "Zacks Commentary" (by Zacks Equity Research)
3 Healthcare Mutual Funds to Grab as the Sector Continues to Rebound
JNGLX, VGHCX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
In Article Trend: Somewhat-Bullish
April 22, 2024 (22:08) / "Motley Fool" (by Eric Volkman)
Why Novo Nordisk Topped the Market Today
It's not only spending its capital on developing new drugs.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:21) / "Benzinga" (by Vandana Singh)
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers' spending habits, particularly in the food industry.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:06) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 April 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
)
April 22, 2024 (02:05) / "Business Standard" (by Press Trust of India)
India's role in medical product space represents unique opportunity: FDA
The role of India in the medical product field represents both a unique opportunity and an important responsibility, the head of the US Food and Drug Administration has said, ahead of the annual India-US BioPharma & Healthcare Summit. The summit will take place in Boston later this week.
In Article Trend: Bullish
April 21, 2024 (11:41) / "Associated Press" (by WILL WEISSERT)
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It's not that clear-cut
What the cost of insulin may mean for Biden's campaign The Associated Press ...
In Article Trend: Somewhat-Bullish
April 20, 2024 (13:45) / "Motley Fool" (by Alex Carchidi)
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
These stocks probably won't be getting much cheaper.
In Article Trend: Somewhat-Bullish
April 20, 2024 (12:30) / "Motley Fool" (by David Jagielski)
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
In Article Trend: Neutral
April 20, 2024 (10:48) / "Motley Fool" (by David Jagielski)
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both.
In Article Trend: Somewhat-Bullish
April 19, 2024 (14:33) / "PR Newswire" (by 360iResearch)
Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
PUNE, India, April 19, 2024 /PRNewswire/ -- The report titled "Peptide Therapeutics Market by Technology ( Hybrid Phase, Liquid Phase, Solid Phase ) , Drug Class ( Adrenocorticotropic Hormone, Calcitonin, Insulin ) , Route of Administration, Application, End User, Manufacturing Type - Global ...
In Article Trend: Bullish
April 19, 2024 (12:15) / "Motley Fool" (by David Jagielski)
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
In Article Trend: Somewhat-Bullish
April 18, 2024 (17:55) / "Benzinga" (by Vandana Singh)
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline - Novo Nordisk ( NYSE:NVO )
Thursday, Germany's competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Danish pharma giant Novo Nordisk A/S NVO. Cardior is a biotech company focusing on heart diseases, in the case at hand cardiac insufficiency or heart failure.
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:50) / "Benzinga" (by Vandana Singh)
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025 - Eli Lilly and Co ( NYSE:LLY )
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S's NVO Wegvoy ( ...
In Article Trend: Neutral
April 18, 2024 (16:17) / "The Economist" (by The Economist)
Why weight-loss drugs will reshape the world
M 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe's most valuable company and Eli Lilly's market value has more than doubled.
In Article Trend: Bullish
April 18, 2024 (14:33) / "Investors Business Daily" (by ALLISON GATLIN)
Could Eli Lilly's Sleep Apnea News Actually Help This CPAP Maker?
ResMed Stock Reverses Higher As Weight-Loss Drugs Seen Bolstering Its Devices Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (13:53) / "Motley Fool" (by Adam Spatacco)
Is It Too Late to Buy Nvidia Stock?
Nvidia stock has soared over 220% in the last year, but now could still be as good a time as ever for investors to buy some shares.
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:51) / "Zacks Commentary" (by Zacks Equity Research)
Eli Lilly's ( LLY ) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
In Article Trend: Neutral
April 18, 2024 (00:34) / "Forbes" (by Alex Knapp)
InnovationRx: Legislation Could Prevent Pharma Companies From Working With Chinese Contractors
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. ccording to the American Society of Health System Pharmacists, 323 drugs are currently experiencing shortages in the United States, the highest number the organization has seen since it began recording ...
In Article Trend: Neutral
April 17, 2024 (22:51) / "Motley Fool" (by Eric Volkman)
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
In Article Trend: Neutral
April 17, 2024 (15:23) / "CNBC" (by Annika Kim Constantino)
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
In Article Trend: Neutral
April 17, 2024 (14:48) / "Forbes" (by Ty Roush)
Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says
A late-stage trial of Eli Lilly's weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting popular weight loss drugs have the potential to treat conditions other than obesity or type 2 ...
In Article Trend: Neutral
April 17, 2024 (11:03) / "PR Newswire" (by Veeva Systems)
Biopharma Leaders Come Together at Veeva Commercial Summit to Advance Customer-Centric Engagement
Keynote speakers include leaders from Bayer, Genentech, Novo Nordisk, and Takeda sharing strategies for effective commercialization and engagement
In Article Trend: Somewhat-Bullish
April 17, 2024 (10:15) / "CNBC" (by Annika Kim Constantino)
Eli Lilly's Zepbound shows promise as a sleep apnea treatment in late-stage trials
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.
In Article Trend: Neutral
April 16, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.
In Article Trend: Somewhat-Bullish
April 16, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is iShares International Equity Factor ETF ( INTF ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (10:05) / "The Financial Express" (by Health Desk)
US to see surge in new obesity drug launches in next five years: GlobalData
Over the past two decades, there has been a marked increase in obesity rates among US adults, with projections indicating a continuing upward trend. Two blockbuster drug launches within the last few years-Novo Nordisk's Wegovy ( semaglutide ) and Eli Lilly's Mounjaro ( tirzepatide ) -have ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (09:07) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
April 16, 2024 (03:01) / "CNBC" (by Ernestine Siu)
These are the top 5 companies to work for in India, according to LinkedIn
LinkedIn has released its eighth annual list of top companies to work for in India. Companies that prioritized its employees' experience and growth dominated.
In Article Trend: Somewhat-Bullish
April 15, 2024 (17:39) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 April 2024 - This company announcement discloses the data of the transaction ( s ) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
In Article Trend: Neutral
April 15, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today - Novo Nordisk ( NYSE:NVO )
Novo Nordisk NVO has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39.15%. Currently, Novo Nordisk has a market capitalization of $561.38 billion.
In Article Trend: Somewhat-Bullish
April 15, 2024 (15:22) / "Zacks Commentary" (by Sheraz Mian)
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:00) / "Motley Fool" (by Alex Carchidi)
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
The collaboration could help solve challenges for both businesses.
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:30) / "Motley Fool" (by George Budwell)
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
In Article Trend: Somewhat-Bullish
April 15, 2024 (13:00) / "Motley Fool" (by George Budwell)
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:43) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 15 April 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
April 15, 2024 (12:43) / "Zacks Commentary" (by Abhinab Dasgupta)
Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
In Article Trend: Somewhat-Bullish
April 13, 2024 (15:16) / "Investors Business Daily" (by Investor's Business Daily)
Nvidia Leads 5 Stocks Near Buy Points
Nvidia ( NVDA ) and uranium producer Cameco ( CCJ ) lead this weekend's watch list of five stocks near buy points. Both NVDA and CCJ bucked the trend over the past week as the S&P 500 slipped back to its 50-day moving average for the first time since early November.
In Article Trend: Neutral
April 12, 2024 (21:54) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Netflix, Goldman Sachs And The Bitcoin Halving: Investing Action Plan
A seesaw week took a turn for the better, then slammed into a financial-sector sell-off on Friday, following JPMorgan's earnings report. Goldman Sachs ( GS ) , Charles Schwab ( SCHW ) and Bank of America ( BAC ) are next up, with earnings due early in the week.
In Article Trend: Neutral
April 12, 2024 (17:22) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk ( NYSE:NVO )
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.
In Article Trend: Bullish
April 12, 2024 (15:54) / "Benzinga" (by Vandana Singh)
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy - Eli Lilly and Co ( NYSE:LLY )
U.S. District Judge Roy Altman ruled that the drugmaker Eli Lilly And Co LLY cannot rely on state law to stop a compounding pharmacy, RXCompoundStore.com, from marketing its version of the drug tirzepatide. Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weightloss.
In Article Trend: Neutral
April 12, 2024 (14:40) / "Benzinga" (by Vandana Singh)
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee ( PRAC ) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists ( GLP-1 ) and suicidal or self-injurious thoughts and behaviors.
In Article Trend: Somewhat-Bearish
April 12, 2024 (14:13) / "Forbes" (by Trevor Clawson)
Science Angels: Public/Private Fund Aims To Boost Deep Tech Investment
Here's the problem. Collectively speaking, deep-science startups working in fields such as AI, quantum computing and biotech are seen as a vital cornerstone of future economic prosperity but they don't always find it easy to secure early-stage investment.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:33) / "Forbes" (by Ty Roush)
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
Ozempic Not Linked To Suicidal Thoughts, EU Says Forbes ...
In Article Trend: Bearish
April 12, 2024 (13:27) / "CNBC" (by Annika Kim Constantino)
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
In Article Trend: Somewhat-Bearish
April 12, 2024 (12:55) / "GlobeNewswire" (by Chemometec A/S)
Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
April 12, 2024 (12:14) / "Forbes" (by Danielle Chemtob)
Daily: New DOJ Rules Aim To Close 'Gun Show Loophole'
This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. Like many organizations these days, the Oakland International Airport wants a rebrand.
In Article Trend: Neutral
April 12, 2024 (10:30) / "Forbes" (by Giacomo Tognini)
Meet The Billionaire-Owned Company Making Injectors For Blockbuster Drugs Like Ozempic
Billionaire-Owned SHL Medical Makes Injectors For Drugs Like Ozempic Forbes ...
In Article Trend: Neutral
April 11, 2024 (19:07) / "Benzinga" (by Erica Kollmann)
What's Going On With Ginkgo Bioworks Stock? - Ginkgo Bioworks Holdings ( NYSE:DNA )
Ginkgo Bioworks Holdings, Inc. DNA shares are volatile Thursday. The company announced the acquisition of AgBiome's platform assets and the expansion of its strategic partnership with Novo Nordisk A/S NVO.
In Article Trend: Bullish
April 11, 2024 (09:28) / "The Financial Express" (by Health Desk)
Diabetes and obesity drugs are expected to contribute 350 million euros: Gerresheimer
German packaging and medical equipment maker Gerresheimer said that diabetes and diet drugs is expected to contribute 350 million euros ( $376 million ) of annual revenue by the 2026-27 financial year.,
In Article Trend: Somewhat-Bullish
April 11, 2024 (09:00) / "Business Insider" (by Riddhi Kanetkar)
These are the 11 startups most likely to IPO this year, according to analysts.
The 11 Startups Most Likely to IPO in 2024, According to Analysts - Business Insider ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (03:03) / "Benzinga" (by Globe Newswire)
Robbins LLP is Investigating the Acquisition of Catalent, Inc. ( CTLT ) by Novo Holdings - Catalent ( NYSE:CTLT )
SAN DIEGO, April 10, 2024 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Robbins LLP informs investors it is investigating the acquisition of Catalent, Inc. CTLT by Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Gains As Market Dips: What You Should Know
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.
In Article Trend: Neutral
April 10, 2024 (14:50) / "GlobeNewswire" (by Chemometec A/S)
April 10, 2024 (11:15) / "Motley Fool" (by Prosper Junior Bakiny)
2 Healthcare Stocks to Buy Hand Over Fist in April
Don't wait too long to invest in these exciting stocks.
In Article Trend: Somewhat-Bullish
April 10, 2024 (11:02) / "PR Newswire"
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain - PR Newswire
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain PR ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (10:45) / "Motley Fool" (by David Jagielski)
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
It may not be too late to invest in this promising healthcare stock, even though it may look expensive.
In Article Trend: Somewhat-Bullish
April 9, 2024 (23:00) / "Forbes" (by Arianna Johnson)
GLP-1s Like Ozempic, Wegovy Don't Substantially Increase Thyroid Cancer Risk, Study Suggests
Popular diabetes and weight loss drugs like Ozempic and Wegovy, known as GLP-1 medications, were not found to cause a substantial increase in the risk of developing thyroid cancer, according to one of the biggest studies to explore the link, which is the latest research to dive into the highly ...
In Article Trend: Somewhat-Bearish
April 9, 2024 (21:41) / "PR Newswire" (by DelveInsight Business Research)
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (20:05) / "Business Insider" (by Peter Kafka)
How the 'Oh-oh-oh Ozempic' commercial song made a musician $1 million
Ozempic commercial song made 'Magic' musician David Paton $1M - Business Insider ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (16:15) / "Benzinga" (by Benzinga Insights)
Check Out What Whales Are Doing With NVO - Novo Nordisk ( NYSE:NVO )
Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 15 unusual trades. Delving into the details, we found 46% of traders were bullish, while 53% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
April 9, 2024 (10:45) / "Motley Fool" (by Adam Spatacco)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
In Article Trend: Somewhat-Bullish
April 8, 2024 (19:34) / "Zacks Commentary" (by Neena Mishra)
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
We discuss attractive investment opportunities within the healthcare industry.
In Article Trend: Neutral
April 8, 2024 (14:24) / "Investors Business Daily" (by Investor's Business Daily)
Why Sarepta's First-Quarter Report Is Already Dead In The Water
Sarepta Stock Takes A Beating. And It Might Not Be Over Investor's Business Daily ...
In Article Trend: Neutral
April 8, 2024 (13:40) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 08 April 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
April 8, 2024 (10:30) / "Motley Fool" (by Adria Cimino)
This 1 Number May Ensure Eli Lilly's Dominance in the Weight Loss Drug Market
Lilly's stock has climbed in the triple digits over the past 12 months.
In Article Trend: Somewhat-Bullish
April 8, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Invesco S&P International Developed Quality ETF ( IDHQ ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
April 8, 2024 (09:55) / "Motley Fool" (by Adria Cimino)
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news.
In Article Trend: Somewhat-Bullish
April 8, 2024 (05:21) / "The Financial Express" (by Health Desk)
Biocon leads generic race for blockbuster weight loss drugs as patents set to expire soon
Pharma major Biocon is focusing on anti-obesity therapies as patents of blockbuster drugs will start expiring soon. According to a report by Bloomberg News, the patient expiry will open doors to a wave of generic supply for the market that's expected to touch $100 billion by 2030.
In Article Trend: Somewhat-Bullish
April 8, 2024 (02:34) / "Money Control"
Biocon leads India push into weight loss drugs as patents lapse
The Bengaluru-based firm has scored an early win among its peers with the UK approval for the first generic version of liraglutide injectible, which is losing patent protection in November.
In Article Trend: Somewhat-Bullish
)
April 8, 2024 (01:00) / "Business Standard" (by Bloomberg)
Biocon leads India's push into anti-obesity drugs as patents lapse
An employee in protective clothing works inside the research and development center at the Biocon campus in Bengaluru, India Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that's ...
In Article Trend: Somewhat-Bullish
April 7, 2024 (11:15) / "Motley Fool" (by Alex Carchidi)
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
New findings could lead to more growth from their prized medicines.
In Article Trend: Somewhat-Bullish
April 6, 2024 (20:15) / "CNN" (by Jen Christensen)
Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds
The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to a new study.
In Article Trend: Neutral
April 6, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
Eli Lilly's Wegovy Competitor Is Causing Supply Constraints: What It Means for the Stock
Things are going exactly as planned for the biotech giant.
In Article Trend: Somewhat-Bullish
April 6, 2024 (11:45) / "Motley Fool" (by Adam Spatacco)
Is it Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Why A Pullback Is Bullish For IBD Stock Of The Day Novo Nordisk
Novo Nordisk ( NVO ) is Friday's IBD Stock Of The Day. After hitting a record high in March, shares have pulled back amid new developments in the weight-loss drugs frenzy. Last month, Novo said its next-generation weight-loss pill, amycretin, outperformed blockbuster Wegovy in an early-stage ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:19) / "Business Insider" (by Benzinga Insights)
Assessing Novo Nordisk: Insights From 10 Financial Analysts
10 analysts have expressed a variety of opinions on Novo Nordisk ( NYSE:NVO ) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and ...
In Article Trend: Somewhat-Bullish
April 5, 2024 (11:15) / "Motley Fool" (by Alex Carchidi)
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
These businesses should see good times ahead.
In Article Trend: Somewhat-Bullish
April 4, 2024 (13:56) / "CNBC" (by Annika Kim Constantino)
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The drug, made by Sanofi, is a GLP-1 like Novo Nordisk's blockbuster diabetes injection Ozempic and weight loss counterpart ...
In Article Trend: Neutral
April 4, 2024 (13:15) / "Motley Fool" (by Prosper Junior Bakiny)
Viking Therapeutics Just Announced More Positive Results: Time to Buy?
The drugmaker isn't losing momentum.
In Article Trend: Somewhat-Bullish
April 4, 2024 (11:30) / "Motley Fool" (by Adam Spatacco)
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Novo Nordisk is off to a red-hot start in 2024, and its latest deal could represent huge potential.
In Article Trend: Bullish
April 4, 2024 (10:45) / "CNBC" (by Karen Gilchrist)
Danone CEO downplays threat of weight loss drugs on food producers: 'We see ourselves as extremely complementary'
The CEO of French consumer goods giant Danone downplayed the threat of obesity drugs on its food business, arguing that consumers were likely to turn to healthy products as part of their new regime.
In Article Trend: Neutral
April 4, 2024 (10:30) / "Motley Fool" (by Alex Carchidi)
1 Brand-New ( Good ) Reason to Buy Viking Therapeutics Stock Now
Its long-term growth potential looks like it's improving, again.
In Article Trend: Somewhat-Bullish
April 4, 2024 (09:07) / "GlobeNewswire" (by BioPorto A/S)
Notice convening the Annual General Meeting in BioPorto A/S
April 4, 2024Announcement no. ...
In Article Trend: Neutral
April 4, 2024 (08:55) / "Motley Fool" (by Adria Cimino)
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Viking shares have soared recently on optimism about its program.
In Article Trend: Somewhat-Bullish
April 3, 2024 (20:31) / "Motley Fool" (by Eric Volkman)
Why Eli Lilly Stock Topped the Market Today
One analyst following the company believes it could grow its revenue meaningfully this year.
In Article Trend: Somewhat-Bullish
April 3, 2024 (20:07) / "Benzinga" (by Neil Dennis)
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy - Eli Lilly and Co ( NYSE:LLY ) , Amazon.com ( NASDAQ:AMZN )
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company LLY stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.
In Article Trend: Neutral
April 3, 2024 (18:10) / "Business Insider" (by Alex Bitter)
You can now get Ozempic at Costco - but don't expect big savings
You can now get Ozempic at Costco, but don't expect big savings. - Business Insider ...
In Article Trend: Neutral
April 3, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Digital Realty ( DLR ) to Host AI Supercomputer in Denmark
Digital Realty (DLR) announces its selection for hosting Nvidia-Powered AI supercomputer at its data center in Denmark.
In Article Trend: Somewhat-Bullish
April 3, 2024 (17:37) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S NVO has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic ( semaglutide ) will not be available in Germany during the second quarter.
In Article Trend: Neutral
April 3, 2024 (17:33) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
In Article Trend: Neutral
April 3, 2024 (16:39) / "Forbes" (by James Farrell)
What To Know About Jiyoutai-China's First Potential Ozempic Challenger
A Chinese pharmaceutical company is seeking approval to market Jiyoutai, an alternative to Ozempic that could be the first biosimilar drug to compete with Novo Nordisk's weight-loss and diabetes drugs in China ahead of a potential flood of new obesity medicines in the country-especially as Novo ...
In Article Trend: Neutral
April 3, 2024 (14:05) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - Swedbank Robur Fonder AB
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
April 3, 2024 (10:30) / "Motley Fool" (by Adam Spatacco)
Nvidia Is Bringing Artificial Intelligence ( AI ) to the Healthcare Space. Here's How.
Nvidia may be known for its semiconductor chips, but the company is making waves in the healthcare space.
In Article Trend: Somewhat-Bullish
April 3, 2024 (10:29) / "The Financial Express" (by Health Desk)
China develops first biosimilar of globally popular weight loss drug Ozempic; Application submitted for approval
China develops first biosimilar of globally popular weight loss drug Ozempic. Application submitted for approval The Financial Express ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (07:21) / "Benzinga" (by Benzinga Neuro)
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras - Costco Wholesale ( NASDAQ:COST ) , Eli Lilly and Co ( NYSE:LLY )
Costco Wholesale Corporation COST has launched a weight management program to help its members in their weight loss journey. The program will provide access to popular weight loss medications from pharmaceutical giants Eli Lilly and Co LLY and Novo Nordisk A/S NVO.
In Article Trend: Somewhat-Bullish
April 2, 2024 (23:08) / "Fox Business News" (by Daniella Genovese)
Costco launches weight loss program for members
Costco is jumping into the weight loss game by giving members access to sought-after medications such as those made by pharmaceutical giants Eli Lilly and Novo Nordisk.
In Article Trend: Somewhat-Bullish
April 2, 2024 (19:07) / "PR Newswire" (by Tracelink)
TraceLink Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
TraceLink joins the ranks of Nvidia, YouTube, OpenAI, Novo Nordisk and more BOSTON , April 2, 2024 /PRNewswire/ -- TraceLink has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024.
In Article Trend: Bullish
April 2, 2024 (19:07) / "Canada Newswire" (by Inc.)
TraceLink Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
TraceLink joins the ranks of Nvidia, YouTube, OpenAI, Novo Nordisk and more BOSTON , April 2, 2024 /CNW/ -- TraceLink has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2024. This year's list shines a spotlight on businesses that are shaping their ...
In Article Trend: Bullish
April 2, 2024 (18:54) / "Benzinga" (by Vandana Singh)
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc's AZN Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc PFE.
In Article Trend: Somewhat-Bullish
April 2, 2024 (18:41) / "Benzinga" (by Vandana Singh)
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand - Eli Lilly and Co ( NYSE:LLY )
Citi Research has increased the price target for Eli Lilly And Co LLY, reflecting increased anticipated risk-adjusted peak sales for the company's oral small molecule GLP-1 agonist orforglipron as a mono/fixed-dose combination.
In Article Trend: Neutral
April 2, 2024 (16:09) / "Business Insider" (by Surbhi Jain)
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience
Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's ( NYSE:LLY ) strategic positioning and technical resilience present a compelling investment opportunity.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:39) / "Benzinga" (by Surbhi Jain)
Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience - Eli Lilly and Co ( NYSE:LLY )
Despite facing intensified competition in the weight-loss drug market, particularly with the emergence of its own product Zepbound, Eli Lilly & Co's LLY strategic positioning and technical resilience present a compelling investment opportunity. Zepbound boasts impressive weight-loss efficacy in ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:16) / "Benzinga" (by Benzinga Insights)
Smart Money Is Betting Big In NVO Options - Novo Nordisk ( NYSE:NVO )
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 12 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations ...
In Article Trend: Neutral
April 2, 2024 (15:06) / "Benzinga" (by Caleb Naysmith)
Diabetes Drug Made For Under $5 Costs Americans $1,000, Drawing Comparisons To Martin Shrikeli While Juicing Profits for A Drug Giant - Novo Nordisk ( NYSE:NVO )
The stock of Danish drugmaker Novo Nordisk NVO has been on a tear, up over 400% in the past five years. It's been so successful that its nearly $500 billion market cap exceeds Denmark's entire gross domestic product ( GDP ) , where the company is based.
In Article Trend: Neutral
April 2, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Analysts Think Novo Nordisk ( NVO ) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
In Article Trend: Somewhat-Bullish
April 2, 2024 (10:56) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 2 April 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
April 2, 2024 (09:10) / "Motley Fool" (by Adria Cimino)
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area.
In Article Trend: Somewhat-Bullish
April 1, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Novo Nordisk ( NVO ) Fell More Than Broader Market
Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:03) / "Zacks Commentary" (by Abhinab Dasgupta)
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:30) / "Motley Fool" (by Prosper Junior Bakiny)
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations.
In Article Trend: Somewhat-Bullish
March 31, 2024 (22:14) / "Motley Fool" (by David Jagielski)
Is Novo Nordisk the Best Healthcare Stock for You?
Novo Nordisk has been a hot buy in recent years, but in the long run, the stock can still go a whole lot higher.
In Article Trend: Somewhat-Bullish
March 31, 2024 (16:09) / "Forbes" (by Bruce Y. Lee)
The 'Oatzempic Challenge' On TikTok: Here's What You Need To Know
Talk about sowing some wild oats. TikTokers have been adding the word "oat" to Ozempic to name a liquid concoction of oats, water, and lime juice. They've been calling this drink "Oatzempic," even though there's no Ozempic medication in it.
In Article Trend: Neutral
March 31, 2024 (13:31) / "Motley Fool" (by Adam Spatacco)
Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why.
Viking Therapeutics may be the next company to enter the red-hot weight loss space.
In Article Trend: Neutral
March 31, 2024 (12:15) / "Motley Fool" (by Alex Carchidi)
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
The semaglutide maker just announced a strategic acquisition that will be a green flag for its future value.
In Article Trend: Somewhat-Bullish
March 30, 2024 (15:59) / "The Economist" (by The Economist)
Could weight-loss drugs eat the world?
T monster is a poisonous North American lizard that measures around 50 centimetres and sports a distinctive coat of black and orange scales.
In Article Trend: Neutral
March 30, 2024 (08:19) / "Benzinga" (by Rounak Jain)
Bernie Sanders Slams 'Outrageous' Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO - Novo Nordisk ( NYSE:NVO )
Sen. Bernie Sanders ( I-Vt. ) has taken a stand against the "outrageous" prices of diabetes drug Ozempic by Novo Nordisk NVO. He is considering hearings on the issue and is seeking a meeting with the company's CEO to discuss reducing the drug's price.
In Article Trend: Neutral
March 29, 2024 (16:38) / "Business Insider" (by Hilary Brueck)
A new Ozempic rival helps patients lose fat, but keep their muscle - the holy grail for a weight-loss drug
New GLP-1 weight loss drug mimics effects of exercise with a shot - Business Insider ...
In Article Trend: Neutral
March 29, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Novo Nordisk ( NVO ) is a Top Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:15) / "Motley Fool" (by David Jagielski)
Is It Too Late to Buy Viking Therapeutics Stock?
Shares of Viking Therapeutics have skyrocketed more than 350% this year.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:00) / "Motley Fool" (by Prosper Junior Bakiny)
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Both stocks are pretty risky, but one of them more so than the other.
In Article Trend: Somewhat-Bullish
March 29, 2024 (08:43) / "Motley Fool" (by David Jagielski)
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?
In Article Trend: Neutral
March 29, 2024 (06:24) / "Benzinga" (by Shanthi Rexaline)
Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1? - SPDR S&P 500 ( ARCA:SPY )
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried about the sustainability of the uptrend. How long will the party last? What are the risks involved in investing in an overbought market?
In Article Trend: Somewhat-Bullish
March 28, 2024 (18:42) / "Benzinga" (by Vandana Singh)
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst - Scholar Rock Holding ( NASDAQ:SRRK )
Raymond James has initiated coverage on Scholar Rock Holding SRRK, supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle loss.
In Article Trend: Somewhat-Bullish
March 28, 2024 (17:55) / "Zacks Commentary" (by Andrew Rocco)
2 Top Biotech Buyout Candidates
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (16:54) / "Benzinga" (by Vandana Singh)
How Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows - Novo Nordisk ( NYSE:NVO )
A recent study suggests that despite Novo Nordisk A/S's NVO high monthly charge of close to $1,000 for its blockbuster diabetes drug Ozempic ( semaglutide ) in the U.S., it could be produced for less than $5 a month.
In Article Trend: Neutral
March 28, 2024 (15:55) / "Benzinga" (by Globe Newswire)
Fungicides Market Size is projected to reach USD 23,393.85 million by 2031, growing at a CAGR of 4.6%: Straits Research
New York, United States, March 28, 2024 ( GLOBE NEWSWIRE ) -- Modern crop protection against fungal diseases must include fungicides. Due to changes in farming practices and technological advancements, farmers are now encouraged to practice effective pest management.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:52) / "Investors Business Daily" (by IBD STAFF)
Market Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally was mixed in a holiday-shortened week. The Nasdaq fell modestly while the Russell 2000 rose solidly. Many AI and other growth leaders suffered solid to sharp losses. DraftKings ( DKNG ) fell sharply as the NCAA moved to ban special prop bets following claims regarding a pro ...
In Article Trend: Neutral
March 28, 2024 (14:25) / "Benzinga" (by Vandana Singh)
Insurance Coverage For Weight Loss Drugs - Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk's Successful Wegovy For Certain Patients - CVS Health ( NYSE:CVS ) , Novo Nordisk ( NYSE:NVO ) , Elevance Health ( NYSE:ELV )
Some major U.S. health insurers, including CVS Health Inc CVS, Elevance Health Inc ELV, and Kaiser Permanente will start reimbursing for Novo Nordisk A/S's NVO Wegovy, a popular anti-obesity drug, for specific individuals on Medicare who have heart-related conditions.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:01) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Novo Nordisk - Novo Nordisk ( NYSE:NVO )
Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
In Article Trend: Somewhat-Bullish
March 28, 2024 (13:15) / "GlobeNewswire" (by Omega Therapeutics)
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
CAMBRIDGE, Mass., March 28, 2024 ( GLOBE NEWSWIRE ) -- Omega Therapeutics, Inc. ( Nasdaq: OMGA ) ( "Omega" ) , a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the fourth quarter and ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:19) / "Forbes" (by Danielle Chemtob)
Daily: Why Disney's Rising Stock Still Has Room To Run
Forbes Daily: Positive outlook sees Disney stock price continue to rise Forbes ...
In Article Trend: Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Alzheimer's Space Heats Up. Can Eli Lilly's Embattled Drug Catch Up?
Alzheimer's Disease: The Treatment Battle Heats Up Despite Eli Lilly's Setback Investor's Business Daily ...
In Article Trend: Neutral
March 28, 2024 (10:50) / "Motley Fool" (by Adria Cimino)
Prediction: This Will Be the Next "Magnificent Seven" Stock
This particular company's growth is set to take off...
In Article Trend: Somewhat-Bullish
March 27, 2024 (21:58) / "Forbes" (by Katie Jennings)
InnovationRx: Base Editing Pioneer Nicole Gaudelli Joins GV
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. s a postdoctoral researcher at the Broad Institute of MIT and Harvard, Nicole Gaudelli was the co-inventor of a breakthrough in gene editing: the ability to target a single misspelling in DNA code.
In Article Trend: Somewhat-Bullish
March 27, 2024 (21:18) / "Forbes" (by Sara Dorn)
Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy
Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the "outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...
In Article Trend: Neutral
March 27, 2024 (18:30) / "CNBC" (by Annika Kim Constantino)
Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart
The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.
In Article Trend: Neutral
March 27, 2024 (18:15) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Novo Nordisk? - Novo Nordisk ( NYSE:NVO )
Novo Nordisk's NVO short percent of float has fallen 38.64% since its last report. The company recently reported that it has 4.67 million shares sold short, which is 0.27% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:55) / "CNBC" (by Annika Kim Constantino)
Novo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests
Researchers found Novo Nordisk's Ozempic could be manufactured for an estimated 89 cents to $4.73 for a month's supply, figures that include a profit margin.
In Article Trend: Neutral
March 27, 2024 (16:42) / "Zacks Commentary" (by Zacks Equity Research)
Viking ( VKTX ) Up 17% on Encouraging Oral Obesity Drug Data
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:22) / "Investors Business Daily" (by ALLISON GATLIN)
Eli Lilly, IBD Stock Of The Day, Jumps Entry As Obesity Space Heats
Eli Lilly Stock Jumps Entry Point As Weight-Loss Drugs Fervor Heats Up Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:05) / "GlobeNewswire" (by Aeterna Zentaris Inc)
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial ...
In Article Trend: Somewhat-Bullish
March 27, 2024 (10:26) / "Forbes" (by Robert Hart)
Here's Why Ozempic And Mounjaro Rivals Won't Topple Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
The pharmaceutical industry is hooked on weight loss drugs, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the dominance of Novo Nordisk and Eli Lilly is unlikely to be toppled anytime soon.
In Article Trend: Somewhat-Bullish
March 26, 2024 (21:22) / "Barrons" (by Bill Alpert)
BlackRock's Fink Says Capital Markets Can Solve the Retirement Crisis
BlackRock CEO Larry Fink wants to recreate some of the retirement safety net our parents had. In his annual letter to BlackRock shareholders, chief executive Larry Fink talks longingly about his parents' retirement. They invested. They had a pension. They had Social Security. It was enough.
In Article Trend: Neutral
March 26, 2024 (18:50) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients
Three drugmakers are capping out-of-pocket costs for their inhalers. Meanwhile, many digital diabetes management tools aren't all they're cracked up to be.
In Article Trend: Neutral
March 26, 2024 (17:56) / "Investors Business Daily" (by JAMES DETAR)
Dexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.
Dexcom Stock A Leader. Prognosis Good Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (17:48) / "Benzinga" (by Vandana Singh)
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly - Biohaven ( NYSE:BHVN )
Monday, Biohaven's BHVN CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company's experimental obesity drug. Biohaven said it is developing an obesity drug that works differently from Novo Nordisk A/S's NVO and Eli Lilly And Co's LLY popular GLP-1 drugs.
In Article Trend: Neutral
March 26, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk ( NYSE:NVO )
Novo Nordisk NVO has outperformed the market over the past 10 years by 8.32% on an annualized basis producing an average annual return of 19.04%. Currently, Novo Nordisk has a market capitalization of $580.63 billion.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) to Buy Cardior to Boost Heart Disease Pipeline
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:35) / "Motley Fool" (by Alex Carchidi)
Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?
Their joint project is cutting-edge, but it won't pay off immediately.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:21) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Awaits Consumer Confidence Data
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility. The AI-driven rally of the last 15 months is showing no sign of losing pace.
In Article Trend: Neutral
March 26, 2024 (14:07) / "Motley Fool" (by Alex Carchidi)
Viking Therapeutics: Buy, Sell, or Hold?
It has a promising candidate and plenty of cash in hand.
In Article Trend: Neutral
March 26, 2024 (13:53) / "Motley Fool" (by Alex Carchidi)
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
This biotech just got clearance to dive into a deep ocean of a market.
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:02) / "Investors Business Daily" (by ALLISON GATLIN)
Viking Surges After Weight-Loss Pill Beats Forecasts In Just 28 Days
Viking Stock Surges After Weight-Loss Drug Tops Expectations Investor's Business Daily ...
In Article Trend: Neutral
March 26, 2024 (13:00) / "CNBC" (by Annika Kim Constantino)
Viking Therapeutics stock jumps 15% on promising weight loss pill data
The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.
In Article Trend: Neutral
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Vanguard International Dividend Appreciation ETF ( VIGI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (09:51) / "Motley Fool" (by Keith Speights)
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run.
In Article Trend: Somewhat-Bullish
March 26, 2024 (06:33) / "Zacks Commentary" (by Zacks Equity Research)
Wall Street Set to Post Fifth Winning Month Amid Volatility
Wall Street is likely to record the fifth consecutive winning month despite volatility.
In Article Trend: Neutral
March 25, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But Novo Nordisk ( NVO ) Gained Today
Novo Nordisk (NVO) closed the most recent trading day at $129.05, moving +0.23% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 25, 2024 (19:16) / "Benzinga" (by Benzinga Insights)
Looking At Novo Nordisk's Recent Unusual Options Activity - Novo Nordisk ( NYSE:NVO )
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 26 unusual trades. Delving into the details, we found 61% of traders were bullish, while 38% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:07) / "Motley Fool" (by Adam Spatacco)
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market
Artificial intelligence (AI) could play a big role in medical breakthroughs.
In Article Trend: Bullish
March 25, 2024 (13:05) / "Benzinga" (by Avi Kapoor)
Jim Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In' - ARM Holdings ( NASDAQ:ARM ) , Comstock Resources ( NYSE:CRK )
Raymond James Financial, Inc. RJF is now valued more highly than JPMorgan Chase & Co. JPM, according to Jim Cramer. "So, I'm going to have to say, it's too late, we missed it," he said. "Let's find the next one."
In Article Trend: Somewhat-Bullish
March 25, 2024 (11:58) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 25 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
March 25, 2024 (11:00) / "Forbes" (by Dmitry Reykhart)
Council Post: What's Driving Big Pharma's Recent Market Performance?
What's Driving Big Pharma's Recent Market Performance? Forbes ...
In Article Trend: Neutral
March 25, 2024 (10:25) / "Motley Fool" (by Adam Spatacco)
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.
In Article Trend: Somewhat-Bullish
March 25, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
EQS-News: SYNLAB delivers robust performance in FY 2023
EQS-News: SYNLAB delivers robust performance in FY ...
In Article Trend: Somewhat-Bullish
March 24, 2024 (13:15) / "Motley Fool" (by David Jagielski)
Is Viking Therapeutics Stock a Millionaire Maker?
Viking Therapeutics has become one of the hottest healthcare stocks of 2024.
In Article Trend: Somewhat-Bullish
March 24, 2024 (12:00) / "CNBC" (by Annika Kim Constantino)
Amgen wants in on the booming weight loss drug market - and it's taking a different approach
Amgen is testing a monthly injection that works differently and appears to help patients maintain their weight loss even after they stop taking it.
In Article Trend: Neutral
March 23, 2024 (11:00) / "CNBC" (by Annika Kim Constantino)
Here's how much people are willing to spend on weight loss drugs, according to a new survey
Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others - and it's strongly correlated to their annual income.
In Article Trend: Neutral
March 23, 2024 (09:53) / "Motley Fool" (by Keith Speights)
Where Will Viking Therapeutics Stock Be in 10 Years?
Viking's future appears to be very promising, but market dynamics can change.
In Article Trend: Somewhat-Bullish
March 23, 2024 (08:30) / "Motley Fool" (by Keith Speights)
Will Pfizer Be a Trillion-Dollar Stock by 2035?
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.
In Article Trend: Neutral
March 22, 2024 (17:29) / "Benzinga" (by Vandana Singh)
How Are Obesity Drugs And Nvidia Related? Success Of Ozempic, Wegovy Propels Novo Nordisk Foundation To Fund Nvidia-Powered AI Supercomputer For Faster Drug Development - NVIDIA ( NASDAQ:NVDA ) , Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S NVO, the maker of popular diabetes and weight loss drugs like Ozempic and Wegovy, is delving into artificial intelligence. Backed by the Novo Nordisk Foundation, Eviden, a French computing company, is set to construct a supercomputer leveraging Nvidia Corp's NVDA AI technology.
In Article Trend: Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (15:59) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
In Article Trend: Neutral
March 22, 2024 (15:53) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Gets Positive CHMP Opinion for Insulin Icodec
Novo Nordisk (NVO) receives a positive opinion from the CHMP for once-weekly basal insulin icodec for the treatment of diabetes in adults.
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:34) / "Benzinga" (by Vandana Singh)
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co LLY and Novo Nordisk A/S NVS, alleging severe complications after taking their medications to manage diabetes and aid weight loss.
In Article Trend: Neutral
March 22, 2024 (14:30) / "Motley Fool" (by Adam Spatacco)
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
The success of Ozempic and Wegovy has fueled Novo Nordisk stock to new highs.
In Article Trend: Somewhat-Bullish
March 22, 2024 (11:15) / "Motley Fool" (by Adam Spatacco)
Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly just partnered with Amazon to help accelerate distribution of its various treatments.
In Article Trend: Bullish
March 22, 2024 (10:15) / "Motley Fool" (by Prosper Junior Bakiny)
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The mid-cap biotech has succeeded where many others failed.
In Article Trend: Neutral
March 21, 2024 (22:25) / "Forbes" (by Antonio Pequeño IV)
Medicare Will Cover Weight Loss Drug Wegovy For Eligible Members
Medicare will soon cover popular weight loss drug Wegovy for its members, as long as they have heart disease and an increased risk of heart attack and other cardiovascular issues, the federal health insurance program confirmed with Forbes on Thursday, bucking the agency's trend of not providing ...
In Article Trend: Neutral
March 21, 2024 (20:41) / "Associated Press" (by JONEL ALECCIA)
Medicare can pay for obesity drugs like Wegovy in certain heart patients
Medicare can pay for the popular weight-loss drug Wegovy - as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
In Article Trend: Neutral
March 21, 2024 (19:09) / "Investors Business Daily" (by ALLISON GATLIN)
Medicare Will Cover Weight-Loss Drugs - For Some People
Weight-Loss Drugs Win Medicare Coverage. Here's What It Means For Novo Nordisk, Eli Lilly Investor's Business Daily ...
In Article Trend: Neutral
March 21, 2024 (18:43) / "CNBC" (by Annika Kim Constantino)
Medicare can now cover certain weight loss drugs in a big step for patients
Medicare patients can soon get coverage for Novo Nordisk's Wegovy as long as it is prescribed to reduce their risk of heart attacks and strokes.
In Article Trend: Neutral
March 21, 2024 (17:23) / "Benzinga" (by Vandana Singh)
Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health - Novo Nordisk ( NYSE:NVO )
In a significant development, Medicare may extend coverage for Novo Nordisk A/S's NVO weight-loss drug Wegovy ( semaglutide ) to certain members with a history of heart disease.
In Article Trend: Neutral
March 21, 2024 (15:55) / "GlobeNewswire" (by Novo Nordisk A/S)
Awiqli® ( once-weekly basal insulin icodec ) recommended for approval for the treatment of diabetes by the European regulatory authorities
Bagsværd, Denmark, 21 March 2024 - Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending marketing authorisation for Awiqli® ( the brand name for once-weekly basal insulin icodec ) ...
In Article Trend: Neutral
March 21, 2024 (15:18) / "The Atlantic" (by Hannah Giorgis)
The Most Public Weight-Loss Journey in History
Nearly 13 years after the final episode of The Oprah Winfrey Show, it's easy to forget just how vicious the public scrutiny of Winfrey's body was during her talk show's decades-long run.
In Article Trend: Neutral
March 21, 2024 (14:59) / "GlobeNewswire" (by Novo Nordisk A/S)
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo Nordisk A/S held its Annual General Meeting.
In Article Trend: Neutral
March 21, 2024 (14:55) / "Benzinga" (by Zacks)
4 Fidelity Mutual Funds to Buy as Volatility Continues - C3.ai ( NYSE:AI )
Fidelity Investments, one of the largest asset managers in the world, was founded in 1946 and is currently headquartered in Boston, MA. Proven efficiency in fund management and the ability to survive market volatility have enhanced the company's reputation over the years.
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:15) / "Motley Fool" (by David Jagielski)
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
Has Novo Nordisk's already red-hot stock become an even better buy?
In Article Trend: Somewhat-Bullish
March 20, 2024 (21:00) / "Benzinga" (by Neil Dennis)
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Eli Lilly and Co. LLY enjoyed meteoric success with its weight loss drugs Mounjaro and Zepbound - the latter already recording stellar sales only three months after launch in December. Recent data showed that, for the first time since launch, Zepbound filled more U.S. prescriptions in a single ...
In Article Trend: Neutral
March 20, 2024 (19:45) / "Motley Fool" (by Motley Fool Transcribing)
Tencent ( TCEHY ) Q4 2023 Earnings Call Transcript
TCEHY earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
March 20, 2024 (17:07) / "Investors Business Daily" (by Investor's Business Daily)
Is Pfizer Stock, At A Nine-Year Low, A Sell Amid The Search For Its Big Break?
Pfizer ( PFE ) stock is trading at its lowest point in nine years as the drugmaker looks for its next big break after developing the first Covid vaccine with Germany's BioNTech ( BNTX ) . This month, the European Commission approved Pfizer's Prevnar 20, a vaccine to help protect babies and ...
In Article Trend: Neutral
March 20, 2024 (15:00) / "Business Insider" (by Rachel Hosie)
Celebrities who have used buzzy drugs like Ozempic for weight loss - and who's denied it
Stars Who Have Taken Weight Loss Drugs Like Ozempic, Wegovy - Business Insider ...
In Article Trend: Neutral
March 20, 2024 (14:36) / "Benzinga" (by Erica Kollmann)
Novo Nordisk Stock Stalls On Oprah TV Special, But Reddit Traders Believe It's 'Not Done Yet' - Novo Nordisk ( NYSE:NVO )
Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk A/S NVO, weight-loss drug Ozempic and talk show host Oprah Winfrey.
In Article Trend: Neutral
March 20, 2024 (12:30) / "Motley Fool" (by David Jagielski)
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
The gap has been shrinking between these stocks over the past month.
In Article Trend: Neutral
March 20, 2024 (12:00) / "Investors Business Daily" (by MATT KRANTZ)
Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss
Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.
In Article Trend: Somewhat-Bullish
March 20, 2024 (08:54) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics
Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.
In Article Trend: Neutral
March 20, 2024 (08:20) / "Benzinga" (by Benzinga Neuro)
Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses - Less Eating, More Saving - Novo Nordisk ( NYSE:NVO )
Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X ( formerly Twitter ) to share his thoughts on the potential financial benefits of using Ozempic, a weight-loss drug developed by Novo Nordisk A/S NVO.
In Article Trend: Neutral
March 19, 2024 (18:58) / "Zacks Commentary" (by Andrew Rocco)
Time to be "Overweight" Viking Therapeutics
A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.
In Article Trend: Neutral
March 19, 2024 (17:33) / "CNN" (by Olesya Dmitracova)
The maker of Ozempic is funding a new Nvidia-powered AI supercomputer | Business
The maker of Ozempic is funding a new Nvidia-powered AI supercomputer ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:33) / "CNN" (by Olesya Dmitracova)
Ozempic profits are helping fund a new Nvidia-powered AI supercomputer | Business
Ozempic profits are helping fund a new Nvidia-powered AI supercomputer CNN International ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:08) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: The first drug for a common, deadly liver disease is here - and more are coming
Drugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI takes center stage at HIMSS.
In Article Trend: Neutral
March 19, 2024 (14:00) / "Motley Fool" (by Adam Spatacco)
Is Novo Nordisk on the Verge of Another Blockbuster Drug?
Novo Nordisk just received some positive news for its latest obesity drug, amycretin.
In Article Trend: Somewhat-Bullish
March 19, 2024 (13:45) / "Motley Fool" (by Alex Carchidi)
Warning: This Skyrocketing Stock Has a Hidden Risk
Don't bet on this pitfall happening, but know that it's a possibility.
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:30) / "PR Newswire" (by Flagship Pioneering)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...
In Article Trend: Bullish
March 19, 2024 (12:00) / "Forbes" (by Trefis Team)
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
Eli Lilly stock ( NYSE: LLY ) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company's P/S ratio to ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:30) / "Motley Fool" (by Adam Spatacco)
Did Novo Nordisk Just Get a Jump on Eli Lilly?
A recent FDA announcement may have just put one company in the lead.
In Article Trend: Somewhat-Bullish
March 19, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Hartford Multifactor Developed Markets ( ex-US ) ETF ( RODM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (10:16) / "Benzinga" (by Benzinga Neuro)
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport' - Novo Nordisk ( NYSE:NVO )
In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time special that delves into the stigma associated with weight loss drugs like Ozempic and Wegovy.
In Article Trend: Neutral
March 19, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Madrigal has one key advantage over its two huge potential future rivals.
In Article Trend: Somewhat-Bullish
March 19, 2024 (09:34) / "Zacks Commentary" (by Zacks Equity Research)
4 Fidelity Mutual Funds to Buy as Volatility Continues
Invest in Fidelity mutual funds like FPHAX, FDCAX, FMAGX and FDSCX for high returns alongside risk reduction in the current environment.
In Article Trend: Somewhat-Bullish
March 19, 2024 (08:00) / "GlobeNewswire" (by Atos International)
The Novo Nordisk Foundation chooses Eviden to build "Gefion" in Denmark, one of the world's most powerful AI supercomputers
Press Release ...
In Article Trend: Bullish
March 18, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Novo Nordisk (NVO) concluded the recent trading session at $132.89, signifying a +0.39% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 18, 2024 (16:51) / "Benzinga" (by Vandana Singh)
Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits - Novo Nordisk ( NYSE:NVO )
The recent expansion of Novo Nordisk A/S's NVO Wegovy's ( semaglutide ) FDA approval has sparked a debate over insurance coverage for the drug. However, despite its potential health benefits, some employers and health plans remain hesitant to cover the drug due to its high monthly price of ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:21) / "Benzinga" (by Vandana Singh)
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly And Co's LLY much-in-demand weight-loss drug Zepbound ( tirzepatide ) surged ahead with 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk A/S's NVO rival obesity medicine Wegovy ( semglutide ) for the first time since its launch.
In Article Trend: Neutral
March 18, 2024 (14:18) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 18 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
March 18, 2024 (14:16) / "Benzinga" (by Benzinga Insights)
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment - Novo Nordisk ( NYSE:NVO )
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 76% of the investors opened trades with bullish expectations ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Growth & Price Strength Make Novo Nordisk ( NVO ) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:55) / "CNBC" (by Annika Kim Constantino)
Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
In Article Trend: Neutral
March 18, 2024 (12:06) / "Zacks Commentary" (by Abhinab Dasgupta)
Take the Zacks Approach to Beat the Market: NVIDIA, Fastenal, HORIBA in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
In Article Trend: Somewhat-Bullish
March 18, 2024 (11:32) / "GlobeNewswire" (by Chemometec A/S)
March 18, 2024 (11:28) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - AIM International Mutual Funds
ANNOUNCEMENT NO. ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (11:25) / "GlobeNewswire" (by Chemometec A/S)
March 17, 2024 (21:20) / "Forbes" (by Steve Denning)
How The World's Most Valuable Firms Are Upending The Concept Of Management
The Drucker Forum, as part of its five-year effort to develop "the next management," gave us a progress report last week. The theme of its conference in Vienna in November will be: "managing for new levels of value creation and innovation" with a particular focus on "knowledge workers."
In Article Trend: Bullish
March 17, 2024 (18:28) / "Motley Fool" (by Prosper Junior Bakiny)
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
The drugmaker is magnificent in its own right.
In Article Trend: Somewhat-Bullish
March 17, 2024 (13:46) / "Motley Fool" (by Prosper Junior Bakiny)
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
The company continues to impress investors.
In Article Trend: Bullish
March 17, 2024 (13:00) / "Motley Fool" (by Keith Speights)
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
There's no need for delays in buying these great stocks.
In Article Trend: Neutral
March 17, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
In Article Trend: Somewhat-Bullish
March 17, 2024 (08:31) / "Business Insider" (by George Glover)
Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
Ozempic, Wegovy fattening up Denmark's economy, helped dodge recession - Business Insider ...
In Article Trend: Somewhat-Bullish
March 17, 2024 (07:24) / "Motley Fool" (by Cory Renauer)
Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?
Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.
In Article Trend: Somewhat-Bullish
March 16, 2024 (11:00) / "CNBC" (by Annika Kim Constantino)
Weight loss drug Wegovy is now approved for heart health - but that won't mean broad insurance coverage just yet
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say could significantly strain their budgets.
In Article Trend: Neutral
March 15, 2024 (21:07) / "Motley Fool" (by Alex Carchidi)
Is Ginkgo Bioworks Stock a Buy?
There's a lot to like about this business, but it's still a risky bet.
In Article Trend: Neutral
March 15, 2024 (20:35) / "Barrons" (by Josh Nathan-Kazis)
Wegovy and Zepbound Cast Shadow Over Madrigal's Liver Drug
The Food and Drug Administration's approval of a liver drug from Madrigal Pharmaceuticals marks a turning point in the often-agonizing campaign to get a treatment onto the market for the condition known as MASH. It is also a reminder for investors that biopharma is opening other large markets ...
In Article Trend: Neutral
March 15, 2024 (15:30) / "Benzinga" (by Benzinga Insights)
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk ( NYSE:NVO )
Novo Nordisk NVO has outperformed the market over the past 10 years by 8.87% on an annualized basis producing an average annual return of 19.39%. Currently, Novo Nordisk has a market capitalization of $598.14 billion.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:44) / "Investors Business Daily" (by KEN SHREVE)
Nasdaq, S&P 500 Extend Losses; Adobe Sell-Off Casts Pall On Tech; Ulta Beauty Tumbles
Nasdaq, S&P 500 Extend Losses. Adobe Sell-Off Casts Pall On Tech. Ulta Beauty Tumbles Investor's Business Daily ...
In Article Trend: Neutral
March 15, 2024 (14:15) / "Motley Fool" (by Adam Spatacco)
Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic
Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Novo Nordisk ( NVO ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
March 15, 2024 (13:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Don't jump on the bandwaggon too quickly.
In Article Trend: Neutral
March 15, 2024 (13:19) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
In Article Trend: Somewhat-Bullish
March 15, 2024 (12:08) / "Business Insider" (by Phil Rosen)
Why weight-loss drugs like Ozempic are a game-changer for the global economy
Weight-loss drugs like Ozempic are game-changers for economic outlook - Business Insider ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (11:46) / "Motley Fool" (by Justin Pope)
Move Over, Tesla! These 6 Stocks Could Replace It in the "Magnificent 7"
Tesla is failing to keep pace with the rest of the Magnificent Seven.
In Article Trend: Somewhat-Bullish
March 15, 2024 (11:19) / "Zacks Commentary" (by Zacks Equity Research)
3 Russell Investments Mutual Funds for Solid Returns
Consider investing in Russell Investments mutual funds like RTITX, RGECX and RTDSX for a diversified portfolio.
In Article Trend: Somewhat-Bullish
March 15, 2024 (10:06) / "Motley Fool" (by Billy Duberstein)
Does Tesla Still Belong in the "Magnificent Seven?"
There's a case to be made that Tesla no longer qualifies as a "must-own" stock along with its six other big tech peers.
In Article Trend: Somewhat-Bullish
March 15, 2024 (09:50) / "Motley Fool" (by Keith Speights)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
In Article Trend: Neutral
March 14, 2024 (22:20) / "CNBC" (by Annika Kim Constantino)
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed - or are still trying to break into.
In Article Trend: Neutral
March 14, 2024 (15:17) / "Benzinga" (by Benzinga Insights)
Smart Money Is Betting Big In NVO Options - Novo Nordisk ( NYSE:NVO )
Deep-pocketed investors have adopted a bearish approach towards Novo Nordisk NVO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Neutral
March 14, 2024 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Partners Amazon to Deliver Drugs Like Zepbound
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
In Article Trend: Somewhat-Bullish
March 14, 2024 (09:15) / "Motley Fool" (by David Jagielski)
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.
The risk is higher, but so is the upside when it comes to Zealand Pharma.
In Article Trend: Somewhat-Bullish
March 13, 2024 (23:00) / "CNBC" (by Anna Gleason)
Experts hesitate on weight loss ETFs amid the obesity drug boom
While weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category can achieve the same success.
In Article Trend: Neutral
March 13, 2024 (19:23) / "Forbes" (by Derek Saul)
Tesla's Stock Dip Drops Elon Musk Behind Bezos To World's Third-Richest Person
Tesla shares tanked to a fresh 10-month low Wednesday as Wall Street turns increasingly bearish on the American electric vehicle maker, sending the net worth of Tesla's polarizing centibillionaire CEO Elon Musk plunging.
In Article Trend: Somewhat-Bullish
March 13, 2024 (18:06) / "Fox Business News"
Amazon Pharmacy will deliver Eli Lilly's Zepbound, other drugs to customers' doorsteps
Amazon will now deliver pharmaceutical giant Eli Lilly's diabetes and weight-loss medications to customers' doors. Amazon Pharmacy announced Wednesday that it will serve as a third-party dispensing provider for LillyDirect, the pharmaceutical company's new telehealth site.
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:19) / "Investors Business Daily" (by Investor's Business Daily)
Lilly Teams Up With Amazon To Deliver Weight-Loss Drug
Eli Lilly Taps Amazon Pharmacy To Help Deliver Weight-Loss Drug, Zepbound Investor's Business Daily ...
In Article Trend: Neutral
March 13, 2024 (16:35) / "Benzinga" (by Piero Cingari)
Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs - Agilent Technologies ( NYSE:A ) , Avantor ( NYSE:AVTR )
Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:04) / "Investors Business Daily" (by ALLISON GATLIN)
IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity
Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...
In Article Trend: Neutral
March 13, 2024 (14:31) / "Benzinga" (by Vandana Singh)
Pharmaceutical Crime Jumps 50% As Criminals Seek To Capitalize Rising Tide of Counterfeit Weight-Loss Drugs - Novo Nordisk ( NYSE:NVO )
As the weight-loss frenzy fueled by social media endorsements and Hollywood glamour continues to surge, the battle against counterfeit medications has intensified.
In Article Trend: Neutral
March 13, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights Novo Nordisk, Tesla, Airbnb, ONEOK and CDW
Novo Nordisk, Tesla, Airbnb, ONEOK and CDW are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
March 13, 2024 (13:45) / "Motley Fool" (by Prosper Junior Bakiny)
March 13, 2024 (11:20) / "Forbes" (by Robert Hart)
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs
The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market - here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.
In Article Trend: Neutral
March 13, 2024 (09:03) / "Motley Fool" (by Adria Cimino)
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking aims to enter a market that may be worth $100 billion in a few years.
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:30) / "GlobeNewswire" (by Chemometec A/S)
Appointment of new CEO
ANNOUNCEMENT NO. 255 ( Changed category - Inside information ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:02) / "GlobeNewswire" (by Chemometec A/S)
March 13, 2024 (00:31) / "Motley Fool" (by Eric Volkman)
Why Novo Nordisk Stock Was a Winner Today
A team of analysts believes the popular company has excellent potential for future growth.
In Article Trend: Somewhat-Bullish
March 12, 2024 (22:17) / "The Atlantic" (by Yasmin Tayag)
The Ozempic Revolution Is Stuck
The irony undergirding the new wave of obesity drugs is that they initially weren't created for obesity at all. The profound weight loss spurred by Ozempic, a diabetes drug in the class of so-called GLP-1 agonists, gave way to Wegovy-the same drug, repackaged for obesity.
In Article Trend: Neutral
March 12, 2024 (21:58) / "Zacks Commentary" (by Mark Vickery)
Top Research Reports for Novo Nordisk, Tesla & Airbnb
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Tesla, Inc. (TSLA) and Airbnb, Inc. (ABNB).
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:55) / "Business Insider" (by Phil Rosen)
The dominance of the US economy and the stock market in 4 charts
Stock Market Outlook: US Economic, Market Dominance in 4 Charts - Markets Insider ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
All You Need to Know About Novo Nordisk ( NVO ) Rating Upgrade to Buy
Novo Nordisk (NVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
What Makes Novo Nordisk ( NVO ) a Strong Momentum Stock: Buy Now?
Does Novo Nordisk (NVO) have what it takes to be a top stock pick for momentum investors? Let's find out.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:53) / "Benzinga" (by Vandana Singh)
What's Going On With Fractyl Health Stock Tuesday? - Fractyl Health ( NASDAQ:GUTS )
Tuesday, Fractyl Health Inc GUTS released new preclinical findings for the first clinical candidate in its Rejuva pancreatic gene therapy platform.
In Article Trend: Neutral
March 12, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:00) / "GlobeNewswire" (by Veru Inc.)
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
MIAMI, March 12, 2024 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ: VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome ( ARDS ) , today ...
In Article Trend: Neutral
March 12, 2024 (11:45) / "Motley Fool" (by Alex Carchidi)
1 Big New Reason to Buy Novo Nordisk Stock Hand Over Fist Right This Instant
The pharma giant could have yet another knockout obesity drug on the way.
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:30) / "GlobeNewswire" (by Arecor Therapeutics plc)
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
Arecor Therapeutics plc ( "Arecor" or the "Company" ...
In Article Trend: Bullish
March 12, 2024 (08:53) / "Benzinga" (by Benzinga Neuro)
US Health Agency Reviews Novo Nordisk's Wegovy For Potential Use In Treating Heart Disease Patients With Obesity - Syra Health ( NASDAQ:SYRA ) , Novo Nordisk ( NYSE:NVO )
The Centers for Medicare and Medicaid Services ( CMS ) is considering the inclusion of Novo Nordisk's NVO obesity drug Wegovy in its coverage for heart disease patients with obesity.
In Article Trend: Neutral
March 12, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Indivior Sees Composite Rating Climb To 97
On Tuesday, Indivior ( INDV ) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 97. X The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Indivior is currently forming a cup with handle, with a ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (05:09) / "Benzinga" (by Ananya Gairola)
Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic - 'Shame, Blame And The Weight Loss Revolution' - Novo Nordisk ( NYSE:NVO ) , Eli Lilly and Co ( NYSE:LLY )
Future Fund co-founder Gary Black on Monday shared information about legendary television mogul Oprah Winfrey's upcoming TV special, where she will discuss her weight loss journey and the role of GLP-1 weight loss drugs.
In Article Trend: Neutral
March 12, 2024 (00:22) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( "Catalent" or the "Company" ) ( NYSE: CTLT ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 11, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Novo Nordisk ( NVO ) Dipped More Than Broader Market Today
Novo Nordisk (NVO) concluded the recent trading session at $131.24, signifying a -1.38% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 11, 2024 (17:31) / "Benzinga" (by Vandana Singh)
Anti-Counterfeiting Group Identifies Fake Diabetes Drug Ozempic in 16 Countries: Sparks Patient Harm Concerns - Novo Nordisk ( NYSE:NVO )
In response to growing reports of patient harm caused by counterfeit versions of its popular diabetes drug, Ozempic ( semaglutide ) , Novo Nordisk A/S's NVO CEO, Lars Fruergaard Jorgensen, reportedly affirmed the company is collaborating with authorities across multiple countries.
In Article Trend: Neutral
March 11, 2024 (14:38) / "Benzinga" (by Piero Cingari)
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' - AstraZeneca ( NASDAQ:AZN ) , ASML Holding ( NASDAQ:ASML )
Goldman Sachs has flagged an increasing concern over the U.S. stock market's heavy concentration and the dominant sway of its largest tech stocks, urging investors to broaden their geographical diversification.
In Article Trend: Neutral
March 11, 2024 (13:56) / "Forbes" (by Megan Poinski)
Lumen Technologies' CEO On Their People-First Reset
This is the published version of Forbes' CEO newsletter, which offers the latest news for today's and tomorrow's business leaders and decision makers. Click here to get it delivered to your inbox every Sunday. Admitting that you were wrong is difficult, but it's something leaders do.
In Article Trend: Neutral
March 11, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Novo Nordisk ( NVO ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
March 11, 2024 (12:46) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 11 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
March 11, 2024 (12:03) / "Zacks Commentary" (by Abhinab Dasgupta)
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
In Article Trend: Somewhat-Bullish
March 11, 2024 (10:59) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk's ( NVO ) Wegovy Gets FDA Nod to Reduce Heart Risk
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
In Article Trend: Neutral
March 11, 2024 (10:53) / "Motley Fool" (by Alex Carchidi)
Is Viking Therapeutics Stock a Buy?
Its potential is looking increasingly more likely to be realized.
In Article Trend: Somewhat-Bullish
March 11, 2024 (10:39) / "Zacks Commentary" (by Zacks Equity Research)
3 Fidelity Mutual Funds to Buy Now for Long-Term Growth
Invest in Fidelity mutual funds like FPHAX, FMAGX and FADTX for their reliability and potential for growth.
In Article Trend: Somewhat-Bullish
March 11, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF ( DNL ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (09:30) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - BlackRock, Inc.
ANNOUNCEMENT NO. ...
In Article Trend: Somewhat-Bullish
March 10, 2024 (13:29) / "Motley Fool" (by Keith Speights)
Forget Tesla: I Think This Stock Should Replace It in the "Magnificent Seven"
Tesla doesn't look very magnificent these days. But there's another stock that does.
In Article Trend: Somewhat-Bullish
March 10, 2024 (08:33) / "Motley Fool" (by Cory Renauer)
Is Novo Nordisk a Buy After Its New Obesity Candidate's Success in a Clinical Trial?
Encouraging results recently pushed the pharma stock up to new heights.
In Article Trend: Somewhat-Bullish
March 9, 2024 (22:30) / "The Financial Express" (by Ivinder Gill)
The obese numbers
Obesity is rising at alarming levels. So is its economic impact. Unsurprisingly, the business of weight loss is also getting fatter by the day. It has been dubbed the story of the decade. And, we really didn't need the new Lancet report on rising obesity to tell us that.
In Article Trend: Neutral
March 9, 2024 (21:47) / "Motley Fool" (by David Jagielski)
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest.
In Article Trend: Somewhat-Bullish
March 9, 2024 (17:44) / "Forbes" (by Joshua Cohen)
Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges
A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.
In Article Trend: Neutral
March 9, 2024 (13:05) / "Fox Business News" (by Melissa Rudy)
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug
Wegovy has been approved for use as a heart disease prevention medication, the FDA announced on Friday.
In Article Trend: Neutral
March 9, 2024 (10:52) / "Motley Fool" (by Keith Speights)
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be in store for all three of these drugmakers.
In Article Trend: Somewhat-Bullish
March 9, 2024 (10:07) / "Motley Fool" (by Adria Cimino)
Is Eli Lilly the Best Pharmaceutical Stock for You?
Lilly's recently approved weight-loss drug is off to a good start.
In Article Trend: Somewhat-Bullish
March 9, 2024 (06:14) / "Zacks Commentary" (by Zacks Equity Research)
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
In Article Trend: Neutral
March 9, 2024 (04:25) / "Business Insider" (by markets.businessinsider.com)
FDA Approves Expanded Indication For Novo Nordisk's Wegovy To Reduce Cardiovascular Risk
( RTTNews ) - Novo Nordisk ( NVO ) said that the U.S. Food and Drug Administration has approved an additional indication for Wegovy to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight ...
In Article Trend: Neutral
March 8, 2024 (21:59) / "Benzinga" (by Chris Katje)
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies - Or Could They Get Another Lift? - Eli Lilly and Co ( NYSE:LLY ) , Walt Disney ( NYSE:DIS )
Legendary television mogul Oprah Winfrey recently announced she was stepping down from the board of directors of WeightWatchers. The announcement, along with fourth-quarter financial results, sent shares of WeightWatchers parent WW International WW lower last month.
In Article Trend: Neutral
March 8, 2024 (20:36) / "CNN" (by Meg Tirrell)
Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
Wegovy's not just for weight loss anymore. The US Food and Drug Administration on Friday approved drugmaker Novo Nordisk's application to add cardiovascular benefits to the medicine's label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke or ...
In Article Trend: Neutral
March 8, 2024 (19:58) / "Associated Press" (by JONEL ALECCIA)
Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients
The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, . The U.S.
In Article Trend: Neutral
March 8, 2024 (19:57) / "PR Newswire" (by Novo Nordisk)
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight ... PR ...
In Article Trend: Neutral
March 8, 2024 (19:36) / "Benzinga" (by Piero Cingari)
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S NVO's Wegovy garnered the Food and Drug Administration's approval for expanded use Friday, marking what the drugmaker said is a pivotal turn in the treatment landscape for individuals grappling with the dual challenges of obesity and established cardiovascular disease.
In Article Trend: Neutral
March 8, 2024 (19:31) / "Investors Business Daily" (by Investor's Business Daily)
Novo's Weight-Loss Blockbuster Wins Another Approval
Novo Nordisk Stock Slumps Despite Winning Approval For Weight-Loss Drug For Heart Benefit Investor's Business Daily ...
In Article Trend: Neutral
March 8, 2024 (19:02) / "CNBC" (by Annika Kim Constantino)
Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage
That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients.
In Article Trend: Neutral
March 8, 2024 (18:42) / "GlobeNewswire" (by Novo Nordisk A/S)
Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease
Bagsværd, Denmark, 8 March 2024 - Novo Nordisk today announced that the US Food and Drug Administration ( FDA ) has approved a label expansion for Wegovy® based on a supplemental New Drug Application ( sNDA ) for the indication of reducing risks of major adverse cardiovascular events ( MACE ) ...
In Article Trend: Neutral
March 8, 2024 (17:37) / "CNBC" (by Annika Kim Constantino)
Novo Nordisk CEO says experimental weight loss pill could become a best-in-class drug
Lars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin.
In Article Trend: Neutral
March 8, 2024 (16:23) / "CNN" (by Anna Cooban)
Ozempic or Tesla? Markets are in no doubt which is hotter | Business
Ozempic or Tesla? Markets are in no doubt which is hotter ...
In Article Trend: Neutral
March 8, 2024 (16:12) / "Benzinga" (by Vandana Singh)
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug - Novo Nordisk ( NYSE:NVO )
Novo Nordisk A/S's NVO head of development, Martin Holst Lange, expressed strong confidence in the drugmaker's ability to launch the pill version of its experimental weight loss drug, amycretin, within this decade. The optimism follows the announcement of robust early trial data.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:58) / "Investors Business Daily" (by IBD STAFF)
Market Rally Hits Fresh Highs As Nvidia, Bitcoin Soar: Weekly Review
The stock market rally suffered a sharp loss Tuesday but quickly rebounded, with the S&P 500 and Nasdaq composite hitting record highs. The Dow Jones fell modestly, but pared losses. Nvidia ( NVDA ) and chipmakers led the advance, while some software names struggled.
In Article Trend: Neutral
March 8, 2024 (15:08) / "Investors Business Daily" (by ALLISON GATLIN)
Biogen Surges On A Setback For Lilly's Rival Alzheimer's Drug
Biogen Stock Surges After FDA Delays Its Decision On Eli Lilly's Alzheimer's Treatment Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:03) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Up on Upbeat Data From New Obesity Pill Study
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:59) / "Business Insider" (by Dan DeFrancesco)
Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
Pharma companies are seeing stocks surge thanks to weight-loss drugs - Business Insider ...
In Article Trend: Neutral
March 8, 2024 (13:19) / "Forbes" (by Forbes Daily)
Daily: TikTok Pop-Up Prompts Users To Call Congress Over Ban
This is a published version of the Forbes Daily newsletter, you can sign-up to get Forbes Daily in your inbox here. Vegas oddsmakers would have you believe that the 96th Academy Awards on Sunday will be the Oppenheimer show.
In Article Trend: Neutral
March 8, 2024 (12:08) / "Investors Business Daily" (by Investor's Business Daily)
FDA Delays Decision On Eli Lilly's Alzheimer Drug
The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:47) / "Zacks Commentary" (by Zacks Equity Research)
Viking ( VKTX ) Stock Down on Novo Nordisk's Obesity Pill Data
Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.
In Article Trend: Neutral
March 8, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is Nuveen ESG International Developed Markets Equity ETF ( NUDM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the VanEck Pharmaceutical ETF ( PPH ) ?
Sector ETF report for PPH ...
In Article Trend: Somewhat-Bullish
March 8, 2024 (10:44) / "Zacks Commentary" (by Zacks Equity Research)
Davita ( DVA ) Shares Gain This Week: Will the Rally Continue?
DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.
In Article Trend: Neutral
March 8, 2024 (09:53) / "CNBC" (by Karen Gilchrist)
Novo Nordisk market cap surpasses Tesla on new obesity pill trial data
Wegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.
In Article Trend: Somewhat-Bullish
March 8, 2024 (05:22) / "Benzinga" (by Benzinga Neuro)
Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan - Alphabet ( NASDAQ:GOOG ) , Apple ( NASDAQ:AAPL )
Retail traders have been observed to be selling off their shares in the 'Magnificent Seven' tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan.
In Article Trend: Neutral
March 7, 2024 (22:46) / "Benzinga" (by Maureen Meehan)
Cannabis With Ozempic, Wegovy, Other Weight-Loss Drugs: Here's What You Need To Know If You're Combining Them - Novo Nordisk ( NYSE:NVO )
A new study found that the interaction between cannabis and popular weight-loss drugs such as Ozempic and Wegovy can have an impact on a common test known as a gastric emptying scan, used to evaluate patients with gastrointestinal complaints.
In Article Trend: Neutral
March 7, 2024 (21:55) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT - Catalent ( NYSE:CTLT )
NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ( "Catalent" or the "Company" ) CTLT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 7, 2024 (21:09) / "Business Insider" (by Phil Rosen)
Stock market today: S&P 500, Nasdaq notch records as Powell reiterates rate cuts are coming
Stock Market News Today: S&P 500, Nasdaq Notch Fresh Record Highs - Markets Insider ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:59) / "Forbes" (by Derek Saul)
S&P 500 Sets Another Record-And These Stocks Hit All-Time Highs
S&P 500 Hits Peak As These Stocks Set Records Forbes ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:47) / "Benzinga" (by Vandana Singh)
Eli Lilly's Legal Battle Against Fake Compounded Tirzepatide Products: Bacteria, Impurities Detected - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly And Co LLY revealed on Thursday that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the weight loss treatment Zepbound.
In Article Trend: Neutral
March 7, 2024 (18:18) / "Benzinga" (by Vandana Singh)
Insurance Coverage For Weight Loss Drugs - Cigna Unveils Efforts To Limit Health Plans/Employers Spending - Cigna Group ( NYSE:CI )
Thursday, Evernorth Health Services, a subsidiary of Cigna Group CI introduced a financial guarantee within its EncircleRx program. The move aims to provide clients with predictability when covering GLP-1s, ultimately empowering companies and health plans to exercise better control over their ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:28) / "Forbes" (by Robert Hart)
Ozempic Maker's New Weight Loss Pill Beats Wegovy In Early Trial - What To Know About Novo Nordisk's Amycretin
Ozempic maker Novo Nordisk on Thursday teased a potential successor to its blockbuster weight loss drug Wegovy, the latest in a line of next-generation obesity treatments in development as consumers flock to the powerful drugs and competitors including Eli Lilly, Pfizer and an array of startups ...
In Article Trend: Neutral
March 7, 2024 (17:05) / "Motley Fool" (by Keith Speights)
Why Viking Therapeutics Stock Is Plunging Today
The sell-off could present a buying opportunity for aggressive investors willing to bet that the obesity market will be big enough for multiple winners.
In Article Trend: Neutral
March 7, 2024 (16:49) / "Motley Fool" (by Keith Speights)
Why Novo Nordisk Stock Is Jumping Today ( Hint: It's Not Because of Ozempic or Wegovy )
Novo Nordisk could have another successful obesity drug on the way.
In Article Trend: Bullish
March 7, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Lilly ( LLY ) Up 7.5% Since Last Earnings Report: Can It Continue?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 7, 2024 (16:23) / "Benzinga" (by Akanksha Bakshi)
Bitcoin, Ethereum, Dogecoin Rise As Investors Buy The Dip; Bitcoin Investment For Retirees? Arizona Senate Eyes BTC ETF For Pension Funds; Gold Reaches Unprecedented High Amid Economic Uncertainties - Top Headlines Today While US Was Sleeping
Bitcoin ETFs Dominate With Strong Inflows, Leaving Gold ETFs In The Dust Bitcoin's 'Kimchi Premium', Popularized By Sam Bankman-Fried, Returns To South Korea Amid Record Highs Arthur Hayes Celebrates As 'Dogecoin Killer' Shiba Inu Rolls Out SHIB Names Tokens Early: 'Dog Money Is Taking Over The ...
In Article Trend: Neutral
March 7, 2024 (16:23) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Rise As Fed's Powell Testifies; Nvidia Hits 900 As Tesla Battles 'Possible Loss' Views
Stock Market Today: Stocks Rise As Powell Mentions New Rules. Nvidia Hits 900 While Tesla Losses Feared Investor's Business Daily ...
In Article Trend: Neutral
March 7, 2024 (15:31) / "Business Insider" (by Yuheng Zhan)
Retail traders have been ditching the Magnificent 7 for pharma stocks like Eli Lilly, says JPMorgan
Retail Traders Are Dumping Magnificent 7 for Pharma, JPMorgan Says - Markets Insider ...
In Article Trend: Neutral
March 7, 2024 (15:23) / "Benzinga" (by Avi Kapoor)
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday - Burlington Stores ( NYSE:BURL ) , Kroger ( NYSE:KR ) , American Eagle Outfitters ( NYSE:AEO )
U.S. stocks were higher, with the Dow Jones index gaining more than 150 points on Thursday. Shares of American Eagle Outfitters, Inc. AEO rose during Thursday's session after the company reported better-than-expected fourth-quarter earnings and issued strong three-year revenue outlook strategy.
In Article Trend: Bullish
March 7, 2024 (15:11) / "Forbes" (by Derek Saul)
Ozempic Maker Novo Nordisk More Valuable Than Tesla
Novo Nordisk is now worth more than Elon Musk's electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss treatment.
In Article Trend: Somewhat-Bullish
March 7, 2024 (14:15) / "The Economist" (by The Economist)
A frenzy of innovation in obesity drugs is under way
W have turned out to be blockbusters. And for good reason. For one thing, after centuries of false promises and quackery, these drugs actually work. With nearly half the world's population expected to be obese or overweight by 2030, demand for them is assured.
In Article Trend: Somewhat-Bullish
March 7, 2024 (14:00) / "CNBC" (by Annika Kim Constantino)
Cigna launches effort to cap employer insurance plan spending on weight loss drugs
Cigna's Evernorth struck agreements with Novo Nordisk and Eli Lilly to limit spending increases for those GLP-1s to a maximum of 15% annually.
In Article Trend: Somewhat-Bullish
March 7, 2024 (13:24) / "Investors Business Daily" (by Investor's Business Daily)
Futures Rise Ahead Of More Powell Testimony
Stock Market Today: Dow Jones Rises Ahead Of Powell Testimony As Nvidia Rallies, Tesla Slides Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (13:02) / "Forbes" (by Forbes Daily)
Daily: Ongoing Feud Between Apple And Epic Games Escalates
Forbes Daily: Epic Games says Apple terminated its developer account Forbes ...
In Article Trend: Neutral
March 7, 2024 (12:46) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Stock Hits 52-Week High After Highly Sought After Obesity Drug Trial Data Why Novo Nordisk Stock Is Trading Higher Today - Novo Nordisk ( NYSE:NVO )
Thursday, Novo Nordisk A/S NVO is holding its Capital Markets Day. Its executive management and other members of senior management will provide a full review of strategy, operations, and financial targets.
In Article Trend: Neutral
March 7, 2024 (12:00) / "Forbes" (by Robert Hart)
Novo Nordisk's New Obesity Pill Beats Wegovy In Early Trial
Shares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company's plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like ...
In Article Trend: Neutral
March 7, 2024 (12:00) / "CNN" (by Meg Tirrell)
Maker of blockbuster weight loss drug urges against 'vanity' use in Oscar weekend ad
Ahead of Oscars, maker of blockbuster weight loss drug urges against 'vanity' use in new ad campaign ...
In Article Trend: Neutral
March 7, 2024 (11:44) / "Investors Business Daily" (by ED CARSON)
Novo Nordisk Jumps On Strong Results For New Obesity Drug
Novo Nordisk ( NVO ) said early Thursday that its experimental oral drug amycretin showed a 13.1% weight loss in participants after 12 weeks in a phase 1 trial. Shares of the Danish drug giant jumped, while rival Eli Lilly ( LLY ) fell.
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:42) / "Zacks Commentary" (by Zacks Equity Research)
3 Nationwide Mutual Funds to Enhance Your Portfolio Returns
Consider investing in Nationwide mutual funds like NWAMX, GNWRX and NWHLX for solid returns.
In Article Trend: Somewhat-Bullish
March 7, 2024 (11:22) / "CNBC" (by Elliot Smith)
Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips
Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.
In Article Trend: Neutral
March 7, 2024 (09:31) / "Barrons" (by Joe Woelfel)
NYCB, Novo Nordisk, Ciena, Kroger, Tesla, Rivian, Victoria's Secret, and More Stock Market Movers
NYCB, Tesla, Victoria's Secret, Rush Street, Kroger, Broadcom, and More Stock Movers ...
In Article Trend: Neutral
March 7, 2024 (09:00) / "Business Insider" (by William Edwards)
BANK OF AMERICA: Weight-loss drugs like Ozempic are being supplied or developed by these 16 stocks - and their use is expected to skyrocket by 2035
16 Stocks With Weight-Loss Drugs Like Ozempic Approved or Developing - Business Insider ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (07:20) / "Benzinga" (by Benzinga Neuro)
Ozempic Maker Novo Nordisk To Introduce Obesity Drug Wegovy In Japan, Acknowledging Country's Rising Weight Issue - Novo Nordisk ( NYSE:NVO )
Ozempic maker Novo Nordisk NVO, a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country.
In Article Trend: Neutral
March 7, 2024 (07:00) / "GlobeNewswire" (by Novo Nordisk A/S)
Highlights to be presented at Novo Nordisk's Capital Markets Day 2024
Bagsværd, Denmark, 7 March 2024 - Novo Nordisk is today hosting a Capital Markets Day ( CMD ) where the company is providing a progress update on its Strategic Aspirations 2025.
In Article Trend: Somewhat-Bullish
March 7, 2024 (06:15) / "Barrons" (by Josh Nathan-Kazis)
Biden Will Tout Lower Drug Prices in State of the Union. Big Pharma Might Be Losing the Fight.
Big Pharma Is Running Out of Time to Block Medicare Drug Price Negotiations ...
In Article Trend: Neutral
March 6, 2024 (17:17) / "Benzinga" (by Vandana Singh)
Novo Nordisk's Semaglutide's Multi-Beneficial Effects: Weight Loss, Improved Metabolic Markers, Liver Fat Reduction in HIV-Related Liver Disease - Novo Nordisk ( NYSE:NVO )
The weekly injection of semaglutide has proven to be both safe and effective, reducing liver fat in individuals with HIV and fatty liver disease, as unveiled by data from a mid-stage study sponsored by the National Institutes of Health.
In Article Trend: Neutral
March 6, 2024 (15:25) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom Pops As It Enters A New CGM Market: Non-Diabetics
Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:33) / "Benzinga" (by Vandana Singh)
What's Going With Eli Lilly Stock On Wednesday? - Eli Lilly and Co ( NYSE:LLY )
Eli Lilly LLY is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound ( tirzepatide ) , as it inks deals with key players such as National Resilience and BSP Pharmaceuticals for the filling and "finishing" of its injector pens.
In Article Trend: Neutral
March 6, 2024 (13:34) / "Zacks Commentary" (by Zacks Equity Research)
Novo Nordisk ( NVO ) Down Despite Kidney Outcomes Study Success
Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.
In Article Trend: Neutral
March 6, 2024 (12:45) / "Motley Fool" (by James Brumley)
Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?
It's only a bargain price if it's actually worth owning.
In Article Trend: Neutral
March 6, 2024 (10:50) / "Motley Fool" (by Keith Speights)
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings.
In Article Trend: Somewhat-Bullish
March 5, 2024 (23:23) / "Motley Fool" (by Eric Volkman)
Why Novo Nordisk Stock Tumbled by Nearly 3% on Tuesday
The hotly popular European pharmaceutical company continues to investigate how its most popular molecule can be used for different afflictions.
In Article Trend: Neutral
March 5, 2024 (21:45) / "Benzinga" (by Natan Ponieman)
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca ( NASDAQ:AZN ) , Bristol-Myers Squibb ( NYSE:BMY )
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.
In Article Trend: Neutral
March 5, 2024 (21:01) / "PR Newswire" (by Inc.)
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., March 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ( Nasdaq: RIGL ) today reported financial results for the fourth quarter and full year ended December 31, 2023, including sales of TAVALISSE® ( fostamatinib disodium hexahydrate ) tablets for the treatment of ...
In Article Trend: Neutral
March 5, 2024 (20:21) / "Benzinga" (by Vandana Singh)
Why Are Dialysis Provider Stocks Trading Higher On Tuesday? - Fresenius Medical Care ( NYSE:FMS ) , DaVita ( NYSE:DVA )
Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people ...
In Article Trend: Neutral
March 5, 2024 (17:58) / "The Atlantic" (by Sarah Zhang)
Ozempic Is a Brain Drug
When scientists first created the class of drugs that includes Ozempic, they told a tidy story about how the medications would work: The gut releases a hormone called GLP-1 that signals you're full, so a drug that mimics GLP-1 could do the exact same thing, helping people eat less and lose weight.
In Article Trend: Neutral
March 5, 2024 (17:55) / "Investors Business Daily" (by Investor's Business Daily)
U.S. Stocks Aren't The Only Game In Town, Arm And Novo Please Investors
Looking outside the U.S., 10 names appear in IBD's Global Leaders screen of the IBD Stock Screener, a select list of foreign stocks with strong fundamentals that trade in the U.S. stock market. Arm stock and Novo Nordisk stand out.
In Article Trend: Somewhat-Bullish
March 5, 2024 (16:16) / "Motley Fool" (by Prosper Junior Bakiny)
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
Here's why I'm not worried.
In Article Trend: Neutral
March 5, 2024 (15:40) / "Investors Business Daily" (by ALLISON GATLIN)
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...
In Article Trend: Neutral
March 5, 2024 (15:14) / "Benzinga" (by Akanksha Bakshi)
Bitcoin To Hit $150K By Year-End, Says Fundstrat's Tom Lee: '...A Beeline Back Towards Its Long-Term Trend Line'; Apple's iPhone Sales Dip 24% in China, Falls to Fourth Place Behind Vivo and Huawei - Top Headlines Today While US Was Sleeping
Bitcoin's Rally Captures El Salvador President Nayib Bukele's Attention, Holds The Line With Memes Bitcoin Could Hit $200K This Year, Says Bitwise CIO: 'There's Too Much Demand And Not Enough Supply' Gold Bull Peter Schiff Raises Red Flag For BTC Rally: 'If I Was Long Bitcoin, I Would Be Worried ...
In Article Trend: Neutral
March 5, 2024 (14:53) / "Motley Fool" (by Adam Spatacco)
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:30) / "Zacks Commentary" (by Zacks Equity Research)
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:47) / "CNBC" (by Annika Kim Constantino)
Novo Nordisk's diabetes drug Ozempic slashed the risk of kidney disease progression in trial
The results add to the growing evidence that the highly popular injection has broader health benefits for patients beyond treating Type 2 diabetes.
In Article Trend: Neutral
March 5, 2024 (13:20) / "MarketWatch" (by Ciara Linnane)
Novo Nordisk says Ozempic helped patients with Type 2 diabetes in one new way
The company is planning to file for regulatory approval of a label expansion for Ozempic in the U.S. and European Union in 2024.
In Article Trend: Neutral
March 5, 2024 (12:41) / "Benzinga" (by Vandana Singh)
What's Going On With Novo Nordisk Stock Today? - Novo Nordisk ( NYSE:NVO )
Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW.
In Article Trend: Neutral
March 5, 2024 (11:42) / "Money Control"
How a pharma company is helping transform health of Denmark's economy
The success of Novo Nordisk -- makers of Ozempic and Wegovy, shows the outsized effect a single company can have on a nation ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:24) / "Zacks Commentary" (by Zacks Equity Research)
3 Healthcare Mutual Funds to Buy as the Sector Continues to Grow
JFNAX, VGHCX and FPHAX are three healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.
In Article Trend: Somewhat-Bullish
March 5, 2024 (11:01) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - AIM International Mutual Funds
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
March 5, 2024 (11:00) / "GlobeNewswire" (by Chemometec A/S)
March 5, 2024 (09:53) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Bagsværd, Denmark, 5 March 2024 - Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data ...
In Article Trend: Neutral
March 5, 2024 (06:33) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Says Nvidia, Eli Lilly, Novo Nordisk Are Not Overvalued: 'Will Be Ready To Buy If This Market Sells Off' - NVIDIA ( NASDAQ:NVDA ) , Eli Lilly and Co ( NYSE:LLY )
CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip.
In Article Trend: Somewhat-Bullish
March 5, 2024 (00:08) / "CNBC" (by Julie Coleman)
Cramer says get ready to buy if there's a market sell-off: 'I have my shopping list'
CNBC's Jim Cramer named Nvidia, Eli Lilly and Novo Nordisk as companies that deserve high valuations.
In Article Trend: Neutral
March 4, 2024 (21:03) / "The Economist" (by The Economist)
The battle over the trillion-dollar weight-loss bonanza
W drugs called -1 agonists help users shed fat, and with it the negative health effects of obesity. This can have life-changing effects for the people who take them. It is also increasingly affecting the lives of corporate citizens.
In Article Trend: Neutral
March 4, 2024 (16:17) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Novo Nordisk - Novo Nordisk ( NYSE:NVO )
Investors with a lot of money to spend have taken a bearish stance on Novo Nordisk NVO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
In Article Trend: Neutral
March 4, 2024 (14:29) / "GlobeNewswire" (by Novo Nordisk A/S)
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 04 March 2024 - On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( MAR ) and the Commission Delegated Regulation ( EU ) 2016/1052 of 8 March ...
In Article Trend: Neutral
March 4, 2024 (09:55) / "Motley Fool" (by James Brumley)
This Is the Biggest Company Not in the "Magnificent Seven" -- but It Deserves to Be
It's in a distinctly different business than the "Magnificent Seven" companies, but it deserves the same attention.
In Article Trend: Somewhat-Bullish
March 3, 2024 (17:51) / "Motley Fool" (by Alex Carchidi)
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
This is a close contest, and it'll go on for at least a few more rounds.
In Article Trend: Somewhat-Bullish
March 3, 2024 (17:45) / "Motley Fool" (by Alex Carchidi)
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
It isn't ready for membership today, but it could have a path in the future.
In Article Trend: Somewhat-Bullish
March 3, 2024 (14:45) / "Motley Fool" (by Prosper Junior Bakiny)
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant.
In Article Trend: Somewhat-Bullish
March 3, 2024 (12:48) / "CNBC" (by Annika Kim Constantino)
Viking Therapeutics emerges as a strong weight loss drug player - or takeover target
Some Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data.
In Article Trend: Neutral
March 3, 2024 (12:41) / "Motley Fool" (by Alex Carchidi)
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
The battle for the obesity therapies market is escalating.
In Article Trend: Somewhat-Bullish
March 2, 2024 (14:30) / "Motley Fool" (by and Prosper Junior Bakiny)
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
In Article Trend: Somewhat-Bullish
March 2, 2024 (13:15) / "Motley Fool" (by Adam Spatacco)
Is It Too Late to Buy Eli Lilly Stock Now?
Eli Lilly stock is having a moment, but the company could easily continue soaring.
In Article Trend: Somewhat-Bullish
March 2, 2024 (08:30) / "South China Morning Post" (by Anthony Rowley)
Opinion | Why stock market stars are at odds with real world's investment needs
Investors around the world have been dazzled by the performance of the "Magnificent Seven" US tech stocks and, to a lesser degree, Europe's "Granolas". The size and influence of these giants are taking investment away from essential socioeconomic causes such as climate change, infrastructure and ...
In Article Trend: Neutral
March 2, 2024 (05:00) / "Financial Times" (by Stuart Kirk)
What China can learn from the ashes of my boat
Not a day passes without me screaming at televisions, pepper grinders, lawnmowers or Tupperware. Such poor design. So badly executed. If only Steve Jobs or Sir James Dyson had made you, damn it! Hence my sadness at the news that Apple cars will remain a dream.
In Article Trend: Neutral
March 1, 2024 (23:15) / "Motley Fool" (by Eric Volkman)
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit.
In Article Trend: Bullish
March 1, 2024 (21:58) / "CNN" (by Tami Luhby)
Judge upholds Medicare drug price negotiation program | Politics
Judge upholds Medicare drug price negotiation program, but more lawsuits are being considered in other courts ...
In Article Trend: Neutral
March 1, 2024 (21:57) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings - Catalent ( NYSE:CTLT )
NEW YORK, March 01, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Catalent, Inc. ( "Catalent" or the "Company" ) CTLT stock purchased prior to February 16, 2024.
In Article Trend: Neutral
March 1, 2024 (20:44) / "Benzinga" (by Vandana Singh)
Why Is Eli Lilly Stock Trading Higher Today? - Eli Lilly and Co ( NYSE:LLY )
BofA Securities says Eli Lilly and Company LLY remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% ( compared to the DRG index's +10% ) .
In Article Trend: Bullish
March 1, 2024 (19:02) / "CNBC" (by Annika Kim Constantino)
Judge rejects AstraZeneca's challenge to Medicare drug price negotiations
U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.
In Article Trend: Neutral
March 1, 2024 (17:52) / "MarketWatch" (by Philip van Doorn)
How investors can ride along as a global commodity market shifts away from China
China has long dominated the world market for rare earth minerals, which are required components of many devices.
In Article Trend: Neutral
March 1, 2024 (16:35) / "Investors Business Daily" (by ALLISON GATLIN)
Lilly Stock Could Join The 1,000 Club With $81 Billion In Obesity Sales
Eli Lilly Stock And The Road To 1,000: The $81 Billion Weight-Loss Drugs Space Investor's Business Daily ...
In Article Trend: Neutral
March 1, 2024 (15:34) / "Benzinga" (by Erica Kollmann)
Why Ginkgo Bioworks Stock Is Down After Earnings - Ginkgo Bioworks Holdings ( NYSE:DNA )
Ginkgo Bioworks Holdings, Inc. DNA shares are trading lower Friday after the company posted worse-than-expected fourth-quarter results and issued disappointing guidance. The company reported quarterly losses of 11 cents per share which missed the analyst consensus estimate of losses of 10 cents.
In Article Trend: Somewhat-Bullish
March 1, 2024 (15:32) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Novo Nordisk - Novo Nordisk ( NYSE:NVO )
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk NVO we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations ...
In Article Trend: Neutral
March 1, 2024 (12:31) / "Motley Fool" (by Prosper Junior Bakiny)
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:18) / "Zacks Commentary" (by Zacks Equity Research)
3 Transamerica Mutual Funds for Superb Returns
Invests in Transamerica mutual funds like TWQZX, TIHJX and TLATX for rewarding returns.
In Article Trend: Somewhat-Bullish
March 1, 2024 (06:59) / "Motley Fool" (by Alex Carchidi)
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable.
In Article Trend: Somewhat-Bullish
March 1, 2024 (06:06) / "CNBC" (by Silvia Amaro)
Europe is having its worst earnings season since the onset of Covid - with little hope of a quick turnaround
Looking forward to the next reporting season, however, strategists are pessimistic on the tide turning.
In Article Trend: Neutral
)
March 1, 2024 (01:22) / "Business Standard" (by Bloomberg)
Obesity drugs will not solve our billion-person problem, warns WHO | World News
Obesity drugs will not solve our billion-person problem, warns WHO Business Standard ...
In Article Trend: Neutral
February 29, 2024 (23:44) / "MarketWatch" (by Mark Hulbert)
'GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?
These European and U.S. market darlings both come with spectacular trailing returns, overvaluation and investors' FOMO.
In Article Trend: Somewhat-Bullish
February 29, 2024 (20:00) / "Benzinga" (by Benzinga Insights)
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today - Novo Nordisk ( NYSE:NVO )
Novo Nordisk NVO has outperformed the market over the past 10 years by 7.05% on an annualized basis producing an average annual return of 17.5%. Currently, Novo Nordisk has a market capitalization of $536.06 billion.
In Article Trend: Somewhat-Bullish
February 29, 2024 (14:00) / "Motley Fool" (by Prosper Junior Bakiny)
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
These stocks meet many of the criteria long-term investors look for.
In Article Trend: Somewhat-Bullish
February 29, 2024 (13:50) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:55) / "MarketWatch" (by Ciara Linnane)
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
Viking Therapeutics has a stock offering starting at $85 - a discount from its Wednesday closing price of $94.50.
In Article Trend: Somewhat-Bullish
February 29, 2024 (12:45) / "Motley Fool" (by George Budwell)
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week.
In Article Trend: Neutral
February 29, 2024 (11:42) / "Motley Fool" (by Adria Cimino)
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
Viking stock surged in the triple digits in one trading session.
In Article Trend: Neutral
February 29, 2024 (05:00) / "Motley Fool" (by Motley Fool Transcribing)
Sarepta Therapeutics ( SRPT ) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website